Global Nuclear Medicine/Radiopharmaceuticals Market Size Study & Forecast, by Type (Diagnostic, Therapeutic ), by Application and Regional Forecasts 2025-2035

Description

Valued at approximately USD 6.76 billion in 2024, the Global Nuclear Medicine/Radiopharmaceuticals Market is poised to expand at a robust CAGR of 11.30% over the forecast period 2025-2035. Nuclear medicine, an advanced medical specialty, leverages radiopharmaceuticals to diagnose, monitor, and treat a spectrum of diseases with unparalleled precision. These specialized compounds, infused with radioactive isotopes, play an indispensable role in modern healthcare by enabling early disease detection and targeted therapies that minimize collateral damage to healthy tissue. The surge in chronic disease prevalence, coupled with the rising adoption of personalized medicine and targeted oncology treatments, has propelled demand for nuclear medicine solutions. Additionally, the rapid pace of technological innovation in imaging modalities and isotope production is further reinforcing the market's growth trajectory.

The market's momentum is being fueled by the increasing volume of diagnostic procedures such as PET and SPECT scans, which have become standard in oncology, cardiology, and neurology assessments. As cancer and neurological disorders continue to affect millions globally, nuclear medicine offers a high-sensitivity, non-invasive method to detect abnormalities at their earliest stages, dramatically improving patient outcomes. According to the World Nuclear Association, over 40 million nuclear medicine procedures are performed annually worldwide, with demand expanding at around 5% each year. Furthermore, the therapeutic radiopharmaceuticals segment is gaining remarkable traction due to its proven efficacy in targeted cancer therapy, including prostate and thyroid cancers, as well as its application in pain palliation for bone metastases. However, challenges such as the short half-life of radioisotopes, complex regulatory pathways, and high production costs remain as factors that could temper the market's rapid expansion.

Regionally, North America currently commands the lion's share of the market, underpinned by its advanced healthcare infrastructure, strong research and development capabilities, and widespread adoption of cutting-edge diagnostic technologies. The region benefits from favorable reimbursement frameworks, robust investments in isotope production facilities, and a high concentration of specialized nuclear medicine centers. Meanwhile, Asia Pacific is projected to witness the fastest growth during the forecast period, driven by a rising incidence of chronic diseases, expanding healthcare access, and government-backed initiatives to bolster domestic isotope production in countries like China, India, and Japan. Europe also represents a substantial market, benefiting from established nuclear medicine networks and cross-border collaborations in research and clinical trials, particularly in countries such as Germany, France, and the UK.

Major market player included in this report are:

Bayer AG
Cardinal Health, Inc.
GE Healthcare
Jubilant Pharmova Limited
Lantheus Holdings, Inc.
Siemens Healthineers AG
Bracco Imaging S.p.A
Advanced Accelerator Applications (a Novartis company)
Curium Pharma
Nordion Inc.
EczacIbasI-Monrol Nuclear Products Co.
Telix Pharmaceuticals Limited
IBA Radiopharma Solutions
NorthStar Medical Radioisotopes, LLC
Isotopia Molecular Imaging Ltd.

Global Nuclear Medicine/Radiopharmaceuticals Market Report Scope:

Historical Data - 2023, 2024
Base Year for Estimation - 2024
Forecast period - 2025-2035
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Customization Scope - Free report customization (equivalent up to 8 analysts' working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players. The detailed segments and sub-segments of the market are explained below:

By Type:

Diagnostic
- SPECT (Technetium)
- PET (F-18)
Therapeutic
- Beta Emitters (Y-90)
- Alpha Emitters
- Brachytherapy

By Application:

Neurology
Thyroid
Oncology

By Procedures

By End User

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
UAE
Saudi Arabia
South Africa
Rest of Middle East & Africa

Key Takeaways:

Market Estimates & Forecast for 10 years from 2025 to 2035.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Chapter 1. Global Nuclear Medicine/Radiopharmaceuticals Market Report Scope & Methodology

1.1. Research Objective
1.2. Research Methodology
- 1.2.1. Forecast Model
- 1.2.2. Desk Research
- 1.2.3. Top Down and Bottom-Up Approach
1.3. Research Attributes
1.4. Scope of the Study
- 1.4.1. Market Definition
- 1.4.2. Market Segmentation
1.5. Research Assumption
- 1.5.1. Inclusion & Exclusion
- 1.5.2. Limitations
- 1.5.3. Years Considered for the Study

Chapter 2. Executive Summary

2.1. CEO/CXO Standpoint
2.2. Strategic Insights
2.3. ESG Analysis
2.4. key Findings

Chapter 3. Global Nuclear Medicine/Radiopharmaceuticals Market Forces Analysis

3.1. Market Forces Shaping The Global Nuclear Medicine/Radiopharmaceuticals Market (2024-2035)
3.2. Drivers
- 3.2.1. Escalating PET/SPECT procedure volumes in oncology and neurology driving precision diagnostics
- 3.2.2. Rapid shift toward targeted radioligand therapy and theranostics in personalized medicine
3.3. Restraints
- 3.3.1. Short half-life isotopes and fragile Mo-99/Tc-99m & F-18 supply chains
- 3.3.2. Stringent regulatory pathways and high capital/operational costs for isotope production
3.4. Opportunities
- 3.4.1. Capacity build-outs in Asia Pacific and government-backed domestic isotope production
- 3.4.2. Pipeline of next-gen alpha emitters and expanded indications across oncology & endocrine care

Chapter 4. Global Nuclear Medicine/Radiopharmaceuticals Industry Analysis

4.1. Porter's 5 Forces Model
- 4.1.1. Bargaining Power of Buyer
- 4.1.2. Bargaining Power of Supplier
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
4.2. Porter's 5 Force Forecast Model (2024-2035)
4.3. PESTEL Analysis
- 4.3.1. Political
- 4.3.2. Economical
- 4.3.3. Social
- 4.3.4. Technological
- 4.3.5. Environmental
- 4.3.6. Legal
4.4. Top Investment Opportunities
4.5. Top Winning Strategies (2025)
4.6. Market Share Analysis (2024-2025)
4.7. Global Pricing Analysis And Trends 2025
4.8. Analyst Recommendation & Conclusion

Chapter 5. Global Nuclear Medicine/Radiopharmaceuticals Market Size & Forecasts by Type 2025-2035

5.1. Market Overview
5.2. Global Growth Hormone Deficiency Market Performance - Potential Analysis (2025)
5.3. Diagnostic (SPECT-Technetium, PET-F-18)
- 5.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.3.2. Market size analysis, by region, 2025-2035
5.4. Therapeutic (Beta Emitters-Y-90, Alpha Emitters, Brachytherapy)
- 5.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.4.2. Market size analysis, by region, 2025-2035

Chapter 6. Global Nuclear Medicine/Radiopharmaceuticals Market Size & Forecasts by Application 2025-2035

6.1. Market Overview
6.2. Global Growth Hormone Deficiency Market Performance - Potential Analysis (2025)
6.3. Neurology
- 6.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.3.2. Market size analysis, by region, 2025-2035
6.4. Thyroid
- 6.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.4.2. Market size analysis, by region, 2025-2035
6.5. Oncology
- 6.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.5.2. Market size analysis, by region, 2025-2035

Chapter 7. Global Nuclear Medicine/Radiopharmaceuticals Market Size & Forecasts by Region 2025-2035

7.1. Growth Hormone Deficiency Market, Regional Market Snapshot
7.2. Top Leading & Emerging Countries
7.3. North America Nuclear Medicine/Radiopharmaceuticals Market
- 7.3.1. U.S. Nuclear Medicine/Radiopharmaceuticals Market
  - 7.3.1.1. Type breakdown size & forecasts, 2025-2035
  - 7.3.1.2. Application breakdown size & forecasts, 2025-2035
- 7.3.2. Canada Nuclear Medicine/Radiopharmaceuticals Market
  - 7.3.2.1. Type breakdown size & forecasts, 2025-2035
  - 7.3.2.2. Application breakdown size & forecasts, 2025-2035
7.4. Europe Nuclear Medicine/Radiopharmaceuticals Market
- 7.4.1. UK Nuclear Medicine/Radiopharmaceuticals Market
  - 7.4.1.1. Type breakdown size & forecasts, 2025-2035
  - 7.4.1.2. Application breakdown size & forecasts, 2025-2035
- 7.4.2. Germany Nuclear Medicine/Radiopharmaceuticals Market
  - 7.4.2.1. Type breakdown size & forecasts, 2025-2035
  - 7.4.2.2. Application breakdown size & forecasts, 2025-2035
- 7.4.3. France Nuclear Medicine/Radiopharmaceuticals Market
  - 7.4.3.1. Type breakdown size & forecasts, 2025-2035
  - 7.4.3.2. Application breakdown size & forecasts, 2025-2035
- 7.4.4. Spain Nuclear Medicine/Radiopharmaceuticals Market
  - 7.4.4.1. Type breakdown size & forecasts, 2025-2035
  - 7.4.4.2. Application breakdown size & forecasts, 2025-2035
- 7.4.5. Italy Nuclear Medicine/Radiopharmaceuticals Market
  - 7.4.5.1. Type breakdown size & forecasts, 2025-2035
  - 7.4.5.2. Application breakdown size & forecasts, 2025-2035
- 7.4.6. Rest of Europe Nuclear Medicine/Radiopharmaceuticals Market
  - 7.4.6.1. Type breakdown size & forecasts, 2025-2035
  - 7.4.6.2. Application breakdown size & forecasts, 2025-2035
7.5. Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market
- 7.5.1. China Nuclear Medicine/Radiopharmaceuticals Market
  - 7.5.1.1. Type breakdown size & forecasts, 2025-2035
  - 7.5.1.2. Application breakdown size & forecasts, 2025-2035
- 7.5.2. India Nuclear Medicine/Radiopharmaceuticals Market
  - 7.5.2.1. Type breakdown size & forecasts, 2025-2035
  - 7.5.2.2. Application breakdown size & forecasts, 2025-2035
- 7.5.3. Japan Nuclear Medicine/Radiopharmaceuticals Market
  - 7.5.3.1. Type breakdown size & forecasts, 2025-2035
  - 7.5.3.2. Application breakdown size & forecasts, 2025-2035
- 7.5.4. Australia Nuclear Medicine/Radiopharmaceuticals Market
  - 7.5.4.1. Type breakdown size & forecasts, 2025-2035
  - 7.5.4.2. Application breakdown size & forecasts, 2025-2035
- 7.5.5. South Korea Nuclear Medicine/Radiopharmaceuticals Market
  - 7.5.5.1. Type breakdown size & forecasts, 2025-2035
  - 7.5.5.2. Application breakdown size & forecasts, 2025-2035
- 7.5.6. Rest of APAC Nuclear Medicine/Radiopharmaceuticals Market
  - 7.5.6.1. Type breakdown size & forecasts, 2025-2035
  - 7.5.6.2. Application breakdown size & forecasts, 2025-2035
7.6. Latin America Nuclear Medicine/Radiopharmaceuticals Market
- 7.6.1. Brazil Nuclear Medicine/Radiopharmaceuticals Market
  - 7.6.1.1. Type breakdown size & forecasts, 2025-2035
  - 7.6.1.2. Application breakdown size & forecasts, 2025-2035
- 7.6.2. Mexico Nuclear Medicine/Radiopharmaceuticals Market
  - 7.6.2.1. Type breakdown size & forecasts, 2025-2035
  - 7.6.2.2. Application breakdown size & forecasts, 2025-2035
7.7. Middle East and Africa Nuclear Medicine/Radiopharmaceuticals Market
- 7.7.1. UAE Nuclear Medicine/Radiopharmaceuticals Market
  - 7.7.1.1. Type breakdown size & forecasts, 2025-2035
  - 7.7.1.2. Application breakdown size & forecasts, 2025-2035
- 7.7.2. Saudi Arabia (KSA) Nuclear Medicine/Radiopharmaceuticals Market
  - 7.7.2.1. Type breakdown size & forecasts, 2025-2035
  - 7.7.2.2. Application breakdown size & forecasts, 2025-2035
- 7.7.3. South Africa Nuclear Medicine/Radiopharmaceuticals Market
  - 7.7.3.1. Type breakdown size & forecasts, 2025-2035
  - 7.7.3.2. Application breakdown size & forecasts, 2025-2035

Chapter 8. Competitive Intelligence

8.1. Top Market Strategies
8.2. GE Healthcare
- 8.2.1. Company Overview
- 8.2.2. Key Executives
- 8.2.3. Company Snapshot
- 8.2.4. Financial Performance (Subject to Data Availability)
- 8.2.5. Product/Services Port
- 8.2.6. Recent Development
- 8.2.7. Market Strategies
- 8.2.8. SWOT Analysis
8.3. Siemens Healthineers AG
8.4. Bayer AG
8.5. Lantheus Holdings, Inc.
8.6. Cardinal Health, Inc.
8.7. Bracco Imaging S.p.A
8.8. Curium Pharma
8.9. Advanced Accelerator Applications (Novartis)
8.10. Jubilant Pharmova Limited
8.11. Telix Pharmaceuticals Limited
8.12. Nordion Inc.
8.13. IBA Radiopharma Solutions
8.14. NorthStar Medical Radioisotopes, LLC
8.15. EczacIbasI-Monrol Nuclear Products Co.
8.16. Isotopia Molecular Imaging Ltd.